The Patent Finder

Terms ending in 2042

2SEVENTY Bio, Inc.

Every in-force patent on 2SEVENTY Bio, Inc.'s record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,404,500Homing Endonuclease Variants
In force
 · High confidence
Novo Nordisk A/SIn forceHigh confidence
US 12,297,451Cell Culture Medium
In force
 · High confidence
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
US 12,247,084Anti-Bcma Car Antibodies, Conjugates, and Methods of Use
In force
 · High confidence
2SEVENTY Bio, Inc.In forceHigh confidence
US 12,291,560Dimerizing Agent Regulated Immunoreceptor Complexes
In force
 · High confidence
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
US 12,344,654Mage A4 T Cell Receptors
In force
 · High confidence
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
US 12,454,580FRB Antibodies
In force
 · High confidence
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
6 of 6 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by 2SEVENTY Bio, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited